SiMPLInext SA

The need for predictive models of human tissue engineered in vitro, as alternative to test on animals, has spurred the commercialization of disruptive approaches such as organoids and organ-on-a-chip. These solutions have a high adoption barrier and do not meet a complementary, more specific need which is to extract high quality information from advanced classical in vitro 3D tissue models, as developed for last 40 years. This operation passes necessarily by making them industrially adoptable as required by Global Toxicology Services Markets in Pharma, Chemicals and Consumers Goods. SiMPLInext is offering a complete smart lab equipment kit to unlock high value information from in vitro 3D models and to foster their industrial adoption: the proprietary CoMPLI-SiMPLI SSI® digital platform.